Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · ai

Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD ...

31 July 2026 · By · Wire by Fusion42

Published

31 July 2026

Topic

ai

◆ Sectors

Drug Discovery

◆ Source

Read at insilico.com →

◆ Verified

Fusion42 · 31 July 2026 · Fusion42 review

Insilico Medicine has launched 'Drug Discovery and Development (DDD) Benchmarks as a Service', a standardized evaluation framework to test the real-world performance of AI models in drug discovery tasks, addressing issues of data contamination in existing benchmarks.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 2 sources have reported it between 31 Jul 2026 and 1 Aug 2026.

◆ ◆ The Wire takeaway

Insilico Medicine is now selling the test for the market they compete in. Your AI drug discovery platform now needs to pass their exam to be considered credible by pharma partners.

◆ Coverage

2 sources · first reported 31 Jul 2026 · latest 1 Aug 2026

◆ Related on Wire

◆ Topics

Drug Discoveryaidrug-discoverybenchmarkingpharmafoundation-models